The global uveitis treatment market was valued at $478 million in 2018, and is projected to reach $687 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.
Uveitis is the inflammation of the middle layer of tissue in the eye wall uvea that consists of the iris, choroid, and ciliary body. Different forms of drug such as cycloplegic agents, anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others are used in treatment of uveitis. Different types of uveitis include anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. The most common type of uveitis is an inflammation of the iris called iritis or anterior uveitis.
Increase in prevalence of uveitis and rise in awareness among patient population with increase in adoption of advanced therapeutics is expected to drive the uveitis treatment market growth. In addition, easy accessibility to uveitis therapeutics, rise in demand for uveitis medications, and surge in R&D activities to develop ideal uveitis therapeutics further fuel the market growth. However, unknown etiology and pathophysiology of uveitis is anticipated to hamper the market growth. Furthermore, untapped potential offered by developing economies present lucrative opportunities for the growth of the market during the forecast period. However, lack of specific treatment for uveitis disorder is expected to restrain the growth of the market.
Uveitis Treatment Market Segmentation
The global uveitis treatment market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is classified into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Disease type such as anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis are covered in the report. According to distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
Based on drug class, the uveitis treatment market is categorized into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Currently, anti-inflammatory is major revenue contributing segment and is estimated to significantly grow during the forecast period, owing to adoption of anti-inflammatory as first line treatment for uveitis.
By Drug Class
immunotherapy & targeted therapies is projected as one of the most lucrative segment.
Anti-inflammatory medications are available in the form of eye drops, tablets, or injection form. Eye drops of anti-inflammatory drugs may not penetrate well to the back of the eye, thus this type of treatment is not preferred in posterior uveitis. In case of intermediate or posterior uveitis, and if topical corticosteroid hasn’t worked, corticosteroid injections or shot are used to reduce inflammation. On the other hand, immunotherapy & targeted therapies segment is expected to witness fastest market growth due to rise in demand for ideal therapeutics for treatment of uveitis. Immunosuppressant drugs such as azathioprine, cyclosporine, methotrexate, mycophenolate, and others are available in the uveitis treatment market.
According to disease type, the market is classified into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The anterior uveitis segment is anticipated to depict a significant growth during the forecast period due to higher prevalence of uveitis. Anterior uveitis is most common type of uveitis characterized by an inflammation of the middle layer of the eye, it includes the iris and the adjacent tissue, known as the ciliary body.
By Disease Type
Anterior Uveitis holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Snapshot of Asia-Pacific Uveitis Treatment Market
Asia-Pacific presents lucrative opportunities for the key players operating in the uveitis treatment market, owing to growth in awareness regarding uveitis treatment and rise in adoption of uveitis treatment products. Moreover, improvement in healthcare infrastructure, rise in number of target population, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. In addition, factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the marketand high population base are also expected to drive the growth of the uveitis treatment market in Asia-Pacific.
By Geography
Asia-Pacific region would exhibit the highest CAGR of 6.0% during 2019-2026.
The key players profiled in this report include AbbVie Inc., Alimera Sciences, Inc., Allergan Plc., Amgen Inc., Bausch Health Companies Inc. (Bausch & Lomb Incorporated), Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Mylan N.V., Novartis AG, and Santen Pharmaceutical Co., Ltd.
Key Benefits for Stakeholders:
- The study provides an in-depth analysis of the uveitis treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers uveitis treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize the prevailing opportunities in the market.
- A comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global uveitis treatment market growth.
Uveitis Treatment Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Disease Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Bausch Health Companies Inc. (Bausch & Lomb Incorporated), Mylan N.V., Allergan Plc., Novartis AG, Amgen Inc., Clearside Biomedical, Inc., AbbVie Inc., EyePoint Pharmaceuticals, Inc., Alimera Sciences, Inc., Santen Pharmaceutical Co., Ltd. |
Analyst Review
Uveitis is the inflammation of the middle layer of tissue in the eye wall uvea that consists of the iris, choroid, and ciliary body. The adoption of uveitis treatment is expected to increase due to rise in number target population across the world and growth in awareness regarding advanced uveitis treatment in developing countries.
Rise in number of R&D activities for development of uveitis treatment medication, increase in popularity of advance therapy, and rise in number of target population significantly boost the growth of the uveitis treatment market. However, availability of alternate therapy and adverse effects associated with the use of uveitis therapeutics can hamper the market growth.
North America is expected to remain dominant during the forecast period due to higher number of target population with surge in use of uveitis therapeutics, early detection of the disease, and large presence of trained medical professionals. In addition, presence of advanced healthcare facilities, higher number of R&D activities to develop ideal therapeutics, and strong presence of key players supplement the growth of the market. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period due to rise in number of uveitis affected population with rise in demand for uveitis therapeutics.
Loading Table Of Content...
